Stock MTNB MATINAS BIOPHARMA HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Matinas BioPharma Holdings, Inc.

Equities

MTNB

US5768101058

Real-time Estimate Cboe BZX
Other stock markets
 16:10:09 2024-05-16 EDT 		5-day change 1st Jan Change
0.176 USD +1.97% Intraday chart for Matinas BioPharma Holdings, Inc. -1.70% -19.66%
05-09 Transcript : Matinas BioPharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024
05-09 Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
GL
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
AQ
Transcript : Matinas BioPharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
GL
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting
GL
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
GL
In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
AQ
In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
GL
In Vivo Efficacy of Matinas BioPharma?s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
CI
Matinas BioPharma Prices $10 Million Registered Direct Offering
GL
Matinas BioPharma Prices $10 Million Registered Direct Offering
AQ
Transcript : Matinas BioPharma Holdings, Inc., 2023 Earnings Call, Mar 27, 2024
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
GL
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
AQ
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate, Expanded Use Access Program Achieve Complete Clinical Response
AQ
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
AQ
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
GL
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MTNB Stock
  4. News Matinas BioPharma Holdings, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW